Tetragenetics helps people seeking a cost-effective alternative platform technology for the production of genetically engineered proteins.
Tetragenetics is an early-stage biotechnology company meeting the needs of customers who seek a cost-effective alternative platform technology for the production of genetically engineered proteins. Their technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express in conventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 14, 2016 | Grant | $1.54M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | — | Grant |